Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06445686
Other study ID # 2023-A02063-42
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 2024
Est. completion date February 2026

Study information

Verified date June 2024
Source Biosency
Contact Alexis TOULLEC
Phone 02 21 65 70 01
Email clinical@biosency.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of this study is to assess the feasibility of early detection of acute exacerbations of idiopathic pulmonary fibrosis by the remote monitoring of vital signs. The main question the study aims to answer is: Could a remote monitoring device allow for earlier detection of exacerbations with individualized monitoring and continuous data collection? All patients will receive conventional clinical follow-up based on their health status and clinical recommendations. At the same time, they will benefit from the Bora Care® medical remote monitoring device.


Description:

All patients will receive conventional clinical follow-up based on their health status and clinical recommendations. At the same time, they will benefit from the Bora Care® medical remote monitoring device. To do this, they will be equipped with a Bora Band® connected wristband that measures vital signs at home, and the Bora Box® Gateway that ensures connectivity and allows automatic data uploading in real time to the Bora Connect® data visualization platform. The home healthcare provider Air de Bretagne will be involved in the study to support each patient in the use of the connected wristband. At the end of the follow-up period, the collected data will be retrospectively analysed to identify the most relevant metrics within the time series of vital signs for early detection of Idiopathic Pulmonary Fibrosis exacerbations, and to assess the feasibility of early detection of Idiopathic Pulmonary Fibrosis exacerbations using a score that could trigger an alert prior to the date the patient reports clinical signs or the date the pulmonologist is consulted for exacerbation of Idiopathic Pulmonary Fibrosis. Procedure: - Inclusion Visit : 6-minute walk test and prescription of oxygen therapy - Home Installation Visit: installation of oxygen therapy by Air de Bretagne and setup of the Bora Connect® bracelet and Bora Box® Gateway - Follow-up Visit with the Pulmonologist at 6 months (M6): routine examinations, satisfaction questionnaire, and quality of life questionnaire - End of Study Visit with the Pulmonologist at 12 months (M12): routine examinations, satisfaction questionnaire, and quality of life questionnaire. (In case of exacerbation, the follow-up will be extended by 3 months to collect post-exacerbation data.)


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date February 2026
Est. primary completion date February 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient over 18 years of age, ideally 50% male and 50% female - Patient with IPF with a known level of respiratory function (EFR and blood gas less than 3 months) - Stable patient, i.e. without hospitalisation or exacerbation in the last 3 months - Patient desaturating at 6MW in ambient air (AA) and requiring ambulatory oxygen therapy (SpO2 AA ? 88%) - Patient not receiving walking or permanent oxygen therapy at baseline - Informed patient who has signed consent - Patient affiliated to a social security scheme - Patient not monitored by a home healthcare provider other than Air de Bretagne. Exclusion Criteria: - Vulnerable patient - Patient receiving ambulatory or permanent oxygen therapy at baseline - Patient already seen with another healthcare provider (e.g. OSAS) - Patient unable to use the Bora Band® tool and without access to a caregiver - Presence of co-morbidity considered unstable or very severe by the investigator - Patient protected, under guardianship or incapable of giving free and informed consent

Study Design


Locations

Country Name City State
France Chru Pontchaillou Rennes

Sponsors (4)

Lead Sponsor Collaborator
Biosency Air de Bretagne, Association Fibroses Pulmonaires France, Rennes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assess the feasibility of early detection of acute IPF exacerbations with the Bora Care® Vital Signs Remote Monitoring Solution. Correlation between changes in time series of vital signs (heart rate, respiratory rate) in patients in the days prior to diagnosis of exacerbation of Idiopathic Pulmonary Fibrosis and onset of exacerbation of Idiopathic Pulmonary Fibrosis. 1 year
Secondary Identify relevant metrics in the signals collected by the Bora Care® solution for early detection of medical events. Evolution of vital signs in patients on days prior to the date of other medical events during follow-up. 1 year
Secondary Assess compliance with the use of the Bora Care® bracelet by patients. Number of hours of wearing the Bora Band® bracelet normalised by the total number of hours of the remote monitoring session, information collected via the Bora Care® too. 1 year
Secondary Assess patient satisfaction and reassurance provided by the remote monitoring solution Subjective assessment by the patient of the device of the reassurance provided by the device, of the help to resume physical activity provided by the device, obtained using satisfaction questionnaires at M6 and M12.
SF36 Quality of Life Questionnaire score collected at D0, M6 and M12.
1 year
Secondary Assess the satisfaction and adherence of healthcare professionals to the remote monitoring solution. Subjective assessment of health care professionals' satisfaction with and adherence to the Bora Care® remote monitoring solution, including an organizational impact assessment and an assessment of clinical relevance using a questionnaire at the end of the study. 1 year
Secondary Assess side effects related to the Bora Care® device. Number and nature of Bora Care® adverse events 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05984992 - The First-in-human Study of SRN-001 in Healthy Participants Phase 1
Active, not recruiting NCT04312594 - Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis Phase 2
Recruiting NCT03865927 - GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis Phase 2
Completed NCT03979430 - Early Detection of Acute Exacerbation in Patients With Idiopathic Lung Fibrosis - a Pilot Study N/A
Enrolling by invitation NCT04905693 - Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis Phase 3
Not yet recruiting NCT06241560 - A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood Phase 2
Terminated NCT04419558 - Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Phase 3
Completed NCT03725852 - A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) Phase 2
Terminated NCT03573505 - An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis Phase 2
Recruiting NCT04148157 - Quality of Life in IPF - Patient and Physician Perceptions
Completed NCT03222648 - Structured Exercise Training Programme in Idiopathic Pulmonary Fibrosis N/A
Not yet recruiting NCT06422884 - A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) Phase 2
Completed NCT02257177 - RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients Phase 1/Phase 2
Completed NCT02268981 - Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF) N/A
Withdrawn NCT01524068 - A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations Phase 2
Enrolling by invitation NCT01382368 - Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Phase 4
Completed NCT01199887 - Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis Phase 1
Completed NCT01110694 - Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study
Active, not recruiting NCT02951416 - Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank
Terminated NCT00981747 - Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis Phase 2/Phase 3